Oncology

SubQ Amivantamab Q4W Maintains Efficacy, Improves Convenience: Nicolas Girard, MD, PhD

Enhanced Prophylactic Regimen Reduces Skin AEs With Amivantamab-Lazertinib: Byoung Chul Cho, MD, PhD

PALOMA-2 Reinforces Efficacy of SubQ Amivantamab in EGFR-Mutated NSCLC: Sun Lim Min, MD, PhD

Overcoming Barriers to Widespread Neoadjuvant Lung Cancer Testing: Sandip Patel, MD

Personalizing ctDNA Monitoring Strategies for NSCLC With MET Mutation: Yang Xia, MD, PhD

The Expanding Role of Antibody-Drug Conjugates in Breast Cancer Treatment: Oranus Mohammadi, MD

Real-World Perspectives on ctDNA Applications in Breast Cancer Management: Oranus Mohammadi, MD

Integrating ctDNA Into Breast Cancer Management: Joanne Mortimer, MD, FACP, FASCO

Addressing Learning Curves in Rare NSCLC Subtypes and Targeted Therapy Use: Jorge Nieva, MD

Overcoming Barriers to Molecular Testing in NSCLC Care: Jorge Nieva, MD

Navigating Risk, Treatment, and Reimbursement in Precision Oncology: Sadie Dobrozsi, MD

Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions

Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic

Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman

Oncology Onward: A Conversation With OneOncology’s Dr Jeff Patton

Health Equity Conversations: Improving Diversity of Oncology Care Staff

Lymphoma Research Foundation CEO on Biden’s Cancer Moonshot, Financial Toxicity

Reforming Oncology Care Payments: Interviews From the QCCA Leadership Summit

What Are the Next Steps for Collaboration, Accountability in Oncology Care First?

KOL Corner: Amy Ellis Discusses Value-Based Cancer Rehab With Amanda Hodges